Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Hyperfine, Inc.NASDAQ: HYPR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $3.85M fell 23.7% year over year, ahead of the -26.0% change in trailing-twelve-month research & development. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -14.7% a year.
Context
- Research & development amounted to 128.7% of revenue in FY2025, down 45.9 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -23.7% holds above the trailing-twelve-month pace of -26.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.45M USD
- Year-over-year change
- -22.4%
- 4-year CAGR
- -9.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.45M | -22.4% |
| FY2024 | 2024-12-31 | 22.5M | +0.0% |
| FY2023 | 2023-12-31 | 22.49M | -20.1% |
| FY2022 | 2022-12-31 | 28.16M | +9.0% |
| FY2021 | 2021-12-31 | 25.84M | — |
Research & Development vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 research & development of $16.26M is the 6th highest of the 7 companies compared; the peer median is $19.91M.
- Its year-over-year change of -26.0% is the lowest of 7, against a peer median of +12.6%.
- Research & development amounts to 106.1% of revenue for HYPR, versus a peer median of 25.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $37.8M | +29.2% | -26.9% | 59059.4% | |
IMAImageneBio Inc | LTM Mar 2026 | $30.77M | +23.4% | -23.7% | — |
| LTM Mar 2026 | $20.18M | -5.9% | +14.6% | 27.9% | |
| LTM Mar 2026 | $19.63M | +8.4% | +8.2% | 22.2% | |
| LTM Mar 2026 | $18.17M | +11.9% | +8.6% | — | |
| LTM Mar 2026 | $16.26M | -26.0% | -14.7% | 106.1% | |
| LTM Mar 2026 | $1.77M | +13.3% | +1.8% | 1.7% | |
| Peer median (excluding HYPR) | $19.91M | +12.6% | +5.0% | 25.0% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.5M | 6.81M | 11.03M | 12.89M | 13.56M |
| Cost of Revenue | 2.66M | 5.91M | 6.28M | 7M | 6.81M |
| Gross Profit | (1.17M) | 907K | 4.76M | 5.89M | 6.75M |
| Gross Margin | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Research & Development | 25.84M | 28.16M | 22.49M | 22.5M | 17.45M |
| Selling, General & Admin | 37.86M | 46.63M | 30.38M | 26.62M | 26.39M |
| Operating Expenses | 63.7M | 74.78M | 52.87M | 49.12M | 43.84M |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 2.2M |
| EBITDA | (64.13M) | (72.15M) | (43.18M) | (39.71M) | (33.37M) |
| EBITDA Margin | -4286.4% | -1058.8% | -391.4% | -308.1% | -246.1% |
| Operating Income | (64.87M) | (73.87M) | (48.12M) | (43.22M) | (37.09M) |
| Operating Margin | -4336.1% | -1084.2% | -436.1% | -335.3% | -273.4% |
| Interest Income | 18K | 761K | 3.84M | 2.49M | 1.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17K | 710K | 3.88M | 2.5M | 1.51M |
| Income Before Tax | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Pre-Tax Margin | -4335.0% | -1073.7% | -401.0% | -315.9% | -262.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (64.83M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Net Margin | -4333.8% | -1073.7% | -401.0% | -315.9% | -262.3% |
| EPS (Basic) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| EPS (Diluted) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| Weighted Avg Shares | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
| Weighted Avg Shares (Diluted) | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.